Müller, HL;
Merks, JHM;
Geoerger, B;
Grill, J;
Hargrave, D;
Glade Bender, J;
Gururangan, S;
... Fürst-Recktenwald, S; + view all
(2019)
Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab.
Pediatric Blood and Cancer
, 66
(2)
, Article e27487. 10.1002/pbc.27487.
Preview |
Text
DV-AVA62919_Muller_Integrated analysis manuscript_FINAL_submitted.pdf - Accepted Version Download (174kB) | Preview |
Abstract
BACKGROUND: We conducted an integrated analysis of clinical data to describe long-term effects of bevacizumab on growth and bone development in pediatric and adolescent patients with solid tumors. PROCEDURE: Clinical data were pooled from five phase I/II trials of bevacizumab versus chemotherapy: BERNIE, HERBY, and AVF4117s enrolled newly diagnosed patients, AVF3842s and AVF2771s enrolled patients with relapsed/refractory disease. Height, weight, body mass index (BMI), and bone-age data were pooled by treatment group. Growth charts were used to track and monitor growth in relation to a reference population of healthy children. Bone age was measured based on X-ray of the left hand and wrist. Analyses were exploratory/descriptive. RESULTS: Overall, 268 patients received bevacizumab ± chemotherapy and 135 received chemotherapy alone. Baseline characteristics were generally balanced. Median duration of long-term follow-up was 41.8 months (range, 2.4-75.1) with bevacizumab and 22.9 months (range, 2.8-69.2) with chemotherapy alone. Patients had age-appropriate baseline height and weight. Mean height and weight percentiles decreased over time in both treatment groups, but remained within the normal range (height: mean standard deviation score [SDS] range -2 to +3; weight: mean SDS range -2 to +1). Similar trends were seen in BMI. A tendency for reduced growth velocity relative to the reference population was observed at 6 months and 1 year in both groups, but there was no additional decrease for patients receiving bevacizumab. CONCLUSION: Bevacizumab did not appear to have additional negative effects on growth or development of pediatric and adolescent patients with solid tumors.
| Type: | Article |
|---|---|
| Title: | Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/pbc.27487 |
| Publisher version: | https://doi.org/10.1002/pbc.27487 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | bevacizumab, long-term growth and bone development, pediatrics, pooled analysis, solid tumor |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10068762 |
Archive Staff Only
 |
View Item |
